In addition, we found that the high-risk group of bladder cancer patients receiving PD1/PDL1 treatment response was significantly lower than the low-risk group (13% vs. 31%, p = 0.05), and for PD1/PDL1 treatment in non- responsive patients the risk score was significantly higher than that in the responsive group (p = 0.014) (Figure 7A–7C). This evidence concerns the gene CD274 and urinary bladder cancer.